Anyone notice this little gem ;) per last 10Q may 18th
Sales Representation Agreement
On May 7, 2011, the Company entered into a Sales Representation Agreement (“Agreement”) with Mann Equity, LLC (“Mann”) wherein Mann purchased from the Company the right to sell the Company’s products as an independent distributor for the State of Florida for $5,000. Pursuant to the terms of the one-year agreement, Mann can earn a commission of twenty percent (20%) for each contract sold for network subscription or advertising spots.
Letter of Intent with vitaMedMD, LLC
On May 18, 2011, the Company entered into a non-binding Letter of Intent (“LOI”) with vitaMedMD, LLC, a Delaware limited liability company (“vitaMed”), in which vitaMed will become a wholly owned subsidiary of the Company.
Sales Representation Agreement
On May 7, 2011, the Company entered into a Sales Representation Agreement (“Agreement”) with Mann Equity, LLC (“Mann”) wherein Mann purchased from the Company the right to sell the Company’s products as an independent distributor for the State of Florida for $5,000. Pursuant to the terms of the one-year agreement, Mann can earn a commission of twenty percent (20%) for each contract sold for network subscription or advertising spots.
Letter of Intent with vitaMedMD, LLC
On May 18, 2011, the Company entered into a non-binding Letter of Intent (“LOI”) with vitaMedMD, LLC, a Delaware limited liability company (“vitaMed”), in which vitaMed will become a wholly owned
subsidiary of the Company.
VitaMed is a specialty pharmaceutical company focused on creating value by eliminating inefficiencies in the multi-billion dollar prescription and OTC nutrition and medical foods market while leveraging an innovative, patent-pending informational technology platform. vitaMed primarily markets its products directly to women with the recommendation of their doctor. By significantly eliminating much of the cost associated with the traditional distribution models, vitaMed offers superior-quality products for a lower overall cost to patient and payors while increasing efficiencies for the physician. In addition, vitaMed’s information technology collects and analyzes data designed to improve patient compliance and education, facilitate product development and provide immediate feedback on effectiveness of therapies. The result is increased efficiency and communication between the patient, physician and payor, ultimately creating improved outcomes. The terms of the LOI call for a definitive agreement to be negotiated between the parties prior to June 30, 2011. itaMed is a specialty pharmaceutical company focused on creating value by eliminating inefficiencies in the multi-billion dollar prescription and OTC nutrition and medical foods market while leveraging an innovative, patent-pending informational technology platform. vitaMed primarily markets its products directly to women with the recommendation of their doctor. By significantly eliminating much of the cost associated with the traditional distribution models, vitaMed offers superior-quality products for a lower overall cost to patient and payors while increasing efficiencies for the physician. In addition, vitaMed’s information technology collects and analyzes data designed to improve patient compliance and education, facilitate product development and provide immediate feedback on effectiveness of therapies. The result is increased efficiency and communication between the patient, physician and payor, ultimately creating improved outcomes. The terms of the LOI call for a definitive agreement to be negotiated between the parties prior to June 30, 2011.
AI
